AstraZeneca is in talks to acquire Bristol Myers Squibb in a deal valued at about $400bn. The combination would create the world's fourth-largest drugmaker by market value.
12:00 AMFinancial Times32 stories from 13 sources
Drugmakers chase scale as care systems absorb new strain
Day’s Recap
Supporting Articles
Ebola has killed more than 1,700 people in eastern Congo as the region confronts what is described as the fastest-growing outbreak of the disease.
3:10 PMStat News
An Ebola outbreak in the Democratic Republic of the Congo has killed more than 1,700 people, with nearly 90 percent of reported cases concentrated in Ituri province. The WHO is accelerating clinical trials as the outbreak continues.
7:47 AMAl Jazeera
Novo Nordisk shares fell after the company reported disappointing results for its oral Wegovy candidate, even as it improved its outlook for the year.
4:17 PMMarketWatchNovo Nordisk raised its full-year forecasts for the second time this year, driven by stronger expected sales of its obesity and diabetes medicines. Investors nevertheless sold the stock because the increase fell short of market expectations.
12:48 PMBloomberg Markets
Novo Nordisk's chief executive, Mike Doustdar, says the company is open to large acquisitions and expects some failures as it works to reduce its dependence on weight-loss drugs.
12:00 AMFinancial Times
Pfizer exceeded expectations and raised the lower end of its full-year revenue outlook, supported by Eliquis and other medicines. It nevertheless reduced its expected revenue from Covid products to about $4 billion from roughly $5 billion previously.
1:09 PMCNBC
Robert F. Kennedy Jr. and Mehmet Oz say new policies do not cut Medicaid. State Medicaid directors, however, warn that the changes could cause many people to lose coverage through new eligibility and administrative requirements.
4:30 AMStat News
Palestinian patients who received treatment abroad have returned to Gaza and reunited with their families. Thousands of others remain waiting for medical evacuation, leaving access to essential care dependent on movement across an active conflict zone.
6:04 AMAl Jazeera
The report examines whether AI scribes should be regulated as medical devices in the United Kingdom. It also covers the removal of key U.S. payment pathways for breakthrough devices.
9:23 AMStat News
The article examines how looser or less prescriptive healthcare AI rules could accelerate startup activity and hospital adoption. It argues that reducing regulatory oversight may transfer more responsibility for safety, compliance, and clinical performance to hospitals and clinicians.
4:00 AMPYMNTS
Gilead won a legal case involving its HIV medicine, Eli Lilly moved to broaden access to retatrutide, and other biotech companies reported additional developments. The updates span intellectual property, drug availability, and pipeline expansion.
11:54 AMStat News
Eli Lilly confirmed that more patients will be able to apply for early access to retatrutide, an unapproved obesity drug. The broader briefing also covers a Gilead court victory and other pharmaceutical developments.
9:11 AMStat News12:00 AMFinancial Times
The $400bn megadeal brewing in big pharma
Summary
AstraZeneca is in talks to acquire Bristol Myers Squibb in a deal valued at about $400bn. The combination would create the world's fourth-largest drugmaker by market value.
The talks signal that scale is again becoming a strategic priority in big pharma, as
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A merger would redraw the global pharma landscape and put pressure on rivals to respond with deals of their own.
3:10 PMStat News
Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges
Summary
Ebola has killed more than 1,700 people in eastern Congo as the region confronts what is described as the fastest-growing outbreak of the disease.
The death toll and accelerating spread point to a response under severe strain in a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A fast-growing Ebola outbreak in a fragile health system raises the risk of wider regional transmission and a more difficult international response.
7:47 AMAl Jazeera
DR Congo Ebola outbreak kills more than 1,700 as WHO accelerates trials
Summary
An Ebola outbreak in the Democratic Republic of the Congo has killed more than 1,700 people, with nearly 90 percent of reported cases concentrated in Ituri province. The WHO is accelerating clinical trials as the outbreak continues.
The concentration of cases in Ituri makes the province the decisive front in containing the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The outbreak's scale and geographic concentration are putting emergency response capacity and experimental treatments under immediate pressure.
4:17 PMMarketWatch
Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame
Summary
Novo Nordisk shares fell after the company reported disappointing results for its oral Wegovy candidate, even as it improved its outlook for the year.
The weaker-than-expected pill results deepen concerns about whether Novo Nordisk can extend Wegovy's growth beyond
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The results expose the tension between Novo Nordisk's stronger near-term guidance and doubts about its next major growth engine.
12:48 PMBloomberg Markets
Novo Underwhelms Investors With Soft Wegovy Pill Sales
Summary
Novo Nordisk raised its full-year forecasts for the second time this year, driven by stronger expected sales of its obesity and diabetes medicines. Investors nevertheless sold the stock because the increase fell short of market expectations.
The shift is from demand uncertainty to a higher bar for growth. Novo's flagship drugs
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Strong drug demand is no longer enough to satisfy investors who have priced in exceptional growth.
12:00 AMFinancial Times
‘Arrogance kills’: Novo chief injects risk-taking into Ozempic maker
Summary
Novo Nordisk's chief executive, Mike Doustdar, says the company is open to large acquisitions and expects some failures as it works to reduce its dependence on weight-loss drugs.
Novo is shifting from defending its obesity and diabetes franchise to building a broader pipeline,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The strategy signals that Novo sees its weight-loss dominance as an asset to reinvest, not a sufficient long-term growth plan.
1:09 PMCNBC
Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Summary
Pfizer exceeded expectations and raised the lower end of its full-year revenue outlook, supported by Eliquis and other medicines. It nevertheless reduced its expected revenue from Covid products to about $4 billion from roughly $5 billion previously.
Pfizer’s results show the company is replacing pandemic-era revenue with growth from its broader portfolio,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Pfizer’s recovery now depends on non-Covid medicines carrying the business as pandemic revenues recede.
2 stories · 2 sources
4:30 AMStat News
STAT+: Kennedy and Oz call Medicaid cuts ‘myths.’ It’s more complicated than that
Summary
Robert F. Kennedy Jr. and Mehmet Oz say new policies do not cut Medicaid. State Medicaid directors, however, warn that the changes could cause many people to lose coverage through new eligibility and administrative requirements.
The dispute turns on the difference between reducing the program's budget or benefits and reducing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The policy's real impact will be measured by who remains insured, not by how officials label the changes.
6:04 AMAl Jazeera
Palestinian patients return to Gaza as thousands still await evacuation
Summary
Palestinian patients who received treatment abroad have returned to Gaza and reunited with their families. Thousands of others remain waiting for medical evacuation, leaving access to essential care dependent on movement across an active conflict zone.
The return of treated patients does not resolve the broader evacuation bottleneck. Gaza’s health crisis
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Medical evacuation delays convert a shortage of care into a time-sensitive threat to life and recovery.
9:23 AMStat News
STAT+: Are AI scribes medical devices? U.K. regulator weighs in
Summary
The report examines whether AI scribes should be regulated as medical devices in the United Kingdom. It also covers the removal of key U.S. payment pathways for breakthrough devices.
Regulatory classification will determine the evidence, oversight, and liability requirements for AI scribes used in
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Rules on classification and payment will shape which clinical AI products reach providers and patients.
4:00 AMPYMNTS
Healthcare AI Rules Shift Risk From Regulators to Hospitals
Summary
The article examines how looser or less prescriptive healthcare AI rules could accelerate startup activity and hospital adoption. It argues that reducing regulatory oversight may transfer more responsibility for safety, compliance, and clinical performance to hospitals and clinicians.
The key shift is where accountability sits: fewer front-end regulatory checks leave healthcare providers to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Faster AI adoption could come with greater patient and legal risk if hospitals lack the capacity to evaluate the tools they buy.
11:54 AMStat News
STAT+: Three biotechs with three news updates
Summary
Gilead won a legal case involving its HIV medicine, Eli Lilly moved to broaden access to retatrutide, and other biotech companies reported additional developments. The updates span intellectual property, drug availability, and pipeline expansion.
The developments reinforce three forces shaping biotech: patent protection, access to high-demand medicines, and competition
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Legal decisions and access plans are rapidly reshaping which biotech products can reach patients and generate durable returns.
9:11 AMStat News
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
Summary
Eli Lilly confirmed that more patients will be able to apply for early access to retatrutide, an unapproved obesity drug. The broader briefing also covers a Gilead court victory and other pharmaceutical developments.
Expanded access increases the number of people who may receive retatrutide before approval, while also
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The program tests how drugmakers can respond to intense demand for obesity treatments before approval.
Other Developments
A curated list of other prominent stories from this day.
Attovia Therapeutics, an early-stage drug developer targeting immune system diseases, raised $289 million in a US initial public offering. The shares priced at the top of the marketed range.
9:06 PMBloomberg Markets
Sydney Children's Hospitals Foundation and Scape by the Living Company are launching a program that will provide free accommodation to families of seriously ill children during urgent or extended hospital stays. The initiative is designed to support families connected to New South Wales children's hospitals.
8:31 PMPropertymarkets NewsShionogi plans to add more manufacturing sites in the US over the next decade. Chief Executive Isao Teshirogi said the company is actively pursuing at least three deals.
8:17 PMBloomberg Markets
South Korea's effort to reverse one of the world's lowest fertility rates is colliding with a broader emergency-care breakdown. The shortage is especially severe among doctors who care for high-risk newborns in neonatal intensive care units.
5:00 PMThe New York TimesAfter Annabelle Gurwitch received a stage 4 lung cancer diagnosis, a volunteer living with the same disease urged her to stop fixating on the future and return her attention to living in the present.
4:00 PMNPR Arts
A startup pursuing scalable, custom CRISPR treatments has abandoned its plans. Although the FDA has signaled flexibility for therapies modeled on the Baby KJ case, the regulatory standards remain difficult for a small company to meet.
1:04 PMStat News
Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.
12:56 PMMarketWatch
An engineered chewing gum reduced oral HPV levels by as much as 93% and nearly eliminated two bacteria associated with head and neck cancer. It preserved beneficial oral bacteria in the reported testing.
9:33 AMScienceDaily
Merck raised its revenue outlook as sales of newer medicines grew. It lowered its profit guidance because of a charge linked to its acquisition of Terns Pharmaceuticals.
8:43 AMCNBC
Transgender federal employees are suing over the revocation of their health coverage. The available material also references expanded retatrutide access and the cost of the 2025 measles outbreak, but does not provide details about how those subjects relate to the lawsuit.
8:30 AMStat News
A new analysis questions a federal provision that exempts orphan drugs from Medicare price negotiations. It finds that some recent exemptions may not meet the policy's intended justification.
8:05 AMStat News
The Mamdani administration and a major insurer agreed to pay up to $53 million to reimburse retired city employees who said they were improperly charged $15 medical copays under a retiree health plan.
5:00 AMThe City
A new study of New York’s court-ordered treatment for people with serious mental illness adds evidence to the debate over involuntary care. Its findings raise questions about whether compelled treatment produces the benefits policymakers expect and how such programs affect patients’ rights.
4:30 AMStat News
Researchers found that ovarian cancer cells surviving chemotherapy may release fructose, prompting nearby tumor cells to loosen, escape, and spread. The findings raise possible links to diet and cholesterol-lowering drugs, but have not been confirmed in patients.
1:15 AMScienceDailyWuxi AppTec beat earnings expectations and raised its full-year guidance, prompting Jefferies' Asia healthcare research chief to maintain a positive outlook for the contract research and manufacturing group.
12:28 AMBloomberg Markets
Food-based and other so-called natural alternatives to GLP-1 weight-loss drugs are attracting interest, but their effectiveness remains uncertain and generally lacks the clinical evidence behind prescription treatments.
12:00 AMFinancial Times9:06 PMBloomberg Markets
Goldman-Backed Biotech Attovia Raises $289 Million in US IPO
Summary
Attovia Therapeutics, an early-stage drug developer targeting immune system diseases, raised $289 million in a US initial public offering. The shares priced at the top of the marketed range.
Pricing at the top of the range signals strong investor demand for Attovia despite its
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The deal shows that public markets remain open to select biotech companies with promising disease targets, even before they generate revenue.
8:31 PMPropertymarkets News
Families With Sick Kids to Receive Free Accommodation During Urgent or Extended Hospital Stays
Summary
Sydney Children's Hospitals Foundation and Scape by the Living Company are launching a program that will provide free accommodation to families of seriously ill children during urgent or extended hospital stays. The initiative is designed to support families connected to New South Wales children's hospitals.
The program addresses a practical cost that can compound the stress of prolonged pediatric treatment,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Free nearby housing can remove a major barrier to sustained family presence during critical pediatric treatment.
8:17 PMBloomberg Markets
Shionogi Eyes More US Plants, M&A Deals
Summary
Shionogi plans to add more manufacturing sites in the US over the next decade. Chief Executive Isao Teshirogi said the company is actively pursuing at least three deals.
Shionogi is moving from organic expansion toward a US-focused acquisition program. The targets could increase
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Shionogi’s pipeline of at least three deals signals a broader push to build US manufacturing scale through acquisitions.
5:00 PMThe New York Times
South Korea Wants to Raise Its Birthrate but Doesn’t Have Enough NICU Doctors
Summary
South Korea's effort to reverse one of the world's lowest fertility rates is colliding with a broader emergency-care breakdown. The shortage is especially severe among doctors who care for high-risk newborns in neonatal intensive care units.
The shortage exposes a core constraint on South Korea's population strategy: encouraging births does not
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
South Korea cannot address its demographic crisis through birth incentives alone while critical newborn-care capacity is eroding.
4:00 PMNPR Arts
A volunteer's unexpected advice changed how she faced cancer
Summary
After Annabelle Gurwitch received a stage 4 lung cancer diagnosis, a volunteer living with the same disease urged her to stop fixating on the future and return her attention to living in the present.
The exchange shows how peer support can address a dimension of cancer care that medical
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Peer programs can offer patients emotional guidance that complements clinical care, especially when illness makes the future impossible to predict.
1:04 PMStat News
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
Summary
A startup pursuing scalable, custom CRISPR treatments has abandoned its plans. Although the FDA has signaled flexibility for therapies modeled on the Baby KJ case, the regulatory standards remain difficult for a small company to meet.
Regulatory flexibility has not yet translated into a workable development path for small gene-editing companies.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The setback shows that scientific feasibility does not guarantee a viable path to commercializing individualized gene therapies.
12:56 PMMarketWatch
It’s getting easier for terminally ill people to end their own lives. What to know as laws change.
Summary
Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.
As more jurisdictions change their laws, access will depend increasingly on where patients live and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The policy shift is widening end-of-life options while creating uneven access and new legal and clinical obligations.
9:33 AMScienceDaily
Cancer-fighting chewing gum cuts HPV levels by up to 93%
Summary
An engineered chewing gum reduced oral HPV levels by as much as 93% and nearly eliminated two bacteria associated with head and neck cancer. It preserved beneficial oral bacteria in the reported testing.
The result points to a localized prevention strategy that could reduce cancer-related pathogens without broadly
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A low-cost, noninvasive treatment could expand prevention options for oral HPV and related cancers.
8:43 AMCNBC
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Summary
Merck raised its revenue outlook as sales of newer medicines grew. It lowered its profit guidance because of a charge linked to its acquisition of Terns Pharmaceuticals.
Merck is trading near-term earnings pressure for expanded growth prospects through business development. The higher
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Merck’s update shows how pharmaceutical dealmaking can strengthen future growth while weakening current profit metrics.
8:30 AMStat News
Trans federal employees sue over revoked health coverage
Summary
Transgender federal employees are suing over the revocation of their health coverage. The available material also references expanded retatrutide access and the cost of the 2025 measles outbreak, but does not provide details about how those subjects relate to the lawsuit.
The case puts access to gender-affirming health benefits for federal workers before the courts, with
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The lawsuit could determine whether federal employees retain access to gender-affirming care through their workplace insurance.
8:05 AMStat News
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
Summary
A new analysis questions a federal provision that exempts orphan drugs from Medicare price negotiations. It finds that some recent exemptions may not meet the policy's intended justification.
The analysis challenges the breadth of a protection that can shield drugs from negotiated prices
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The exemptions could preserve higher drug prices while weakening one of Medicare's main cost-control tools.
5:00 AMThe City
City and Insurer to Pay $53 Million Over Retiree Copay Lawsuit
Summary
The Mamdani administration and a major insurer agreed to pay up to $53 million to reimburse retired city employees who said they were improperly charged $15 medical copays under a retiree health plan.
The settlement shifts the financial consequences of the disputed copays to the city and insurer,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The payout offers relief to retirees while adding a substantial liability to the city's health-benefit system.
4:30 AMStat News
STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questions
Summary
A new study of New York’s court-ordered treatment for people with serious mental illness adds evidence to the debate over involuntary care. Its findings raise questions about whether compelled treatment produces the benefits policymakers expect and how such programs affect patients’ rights.
The report comes as the administration promotes court-ordered care, making evidence from New York directly
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Policies that expand involuntary care could affect civil liberties and public spending without clear evidence of better outcomes.
1:15 AMScienceDaily
A common sugar may help cancer cells break free and spread
Summary
Researchers found that ovarian cancer cells surviving chemotherapy may release fructose, prompting nearby tumor cells to loosen, escape, and spread. The findings raise possible links to diet and cholesterol-lowering drugs, but have not been confirmed in patients.
The key shift is from viewing fructose only as a fuel to considering it a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The mechanism could reveal new ways to prevent metastatic relapse in ovarian cancer.
12:28 AMBloomberg Markets
Jefferies' Cui Cui on Wuxi Apptec's Earnings
Summary
Wuxi AppTec beat earnings expectations and raised its full-year guidance, prompting Jefferies' Asia healthcare research chief to maintain a positive outlook for the contract research and manufacturing group.
The guidance increase signals stronger near-term demand and execution than investors expected. That supports Wuxi
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A stronger forecast reinforces the role of outsourced drug development and manufacturing while testing investor confidence in China's biotech infrastructure.
12:00 AMFinancial Times
Do natural GLP-1s work?
Summary
Food-based and other so-called natural alternatives to GLP-1 weight-loss drugs are attracting interest, but their effectiveness remains uncertain and generally lacks the clinical evidence behind prescription treatments.
The market is exploiting demand for cheaper or more accessible substitutes, but biological claims are
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The debate will shape how consumers spend on weight-loss products as demand expands beyond prescription medicines.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!